Reaction
Microangiopathic Haemolytic Anaemia reporting signals
As of the last recalculation, Microangiopathic Haemolytic Anaemia appears in 766 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is SIROLIMUS (PRR 69.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sirolimus | 33 | 69.5 | 69.7 |
| Quinine | 19 | 61.7 | 61.8 |
| Carfilzomib | 39 | 39.4 | 39.5 |
| Tacrolimus Ointment 0.1% | 124 | 32.1 | 32.1 |
| Tacrolimus Extended-Release Capsules | 124 | 32.0 | 32.0 |
| Tacrolimus | 136 | 28.5 | 28.5 |
| Amphotericin B | 12 | 26.4 | 26.4 |
| Posaconazole Delayed-Release | 10 | 25.1 | 25.1 |
| Gemcitabine Hydrochloride | 46 | 25.0 | 25.0 |
| Voriconazole Injection | 19 | 24.4 | 24.4 |
| Ganciclovir | 9 | 24.2 | 24.2 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 23.8 | 23.8 |
| Ganciclovir Sodium | 9 | 23.4 | 23.4 |
| Gemcitabine | 32 | 23.0 | 23.0 |
| Thiotepa | 7 | 20.1 | 20.1 |
| Meropenem | 23 | 20.0 | 20.1 |
| Mycophenilic Acid | 15 | 20.0 | 20.1 |
| Everolimus Tablets | 12 | 19.7 | 19.8 |
| Busulfan | 11 | 19.3 | 19.3 |
| Voriconazole | 20 | 18.3 | 18.4 |
| Eculizumab | 33 | 17.2 | 17.2 |
| Posaconazole | 10 | 16.9 | 16.9 |
| Bevacizumab | 58 | 13.7 | 13.7 |
| Daptomycin | 4 | 11.8 | 11.8 |
| Sunitinib Malate | 15 | 10.6 | 10.6 |
| Oxaliplatin | 27 | 10.2 | 10.2 |
| Ravulizumab | 5 | 10.1 | 10.1 |